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Rapid,  reliable  and  accurate  diagnostic  methods  provide  essential  support  to programmes  that  monitor
and  control  foot-and-mouth  disease  (FMD).  While  pan-speciﬁc  molecular  tests  for FMD  virus  (FMDV)
detection  are  well  established  and  widely  used  in endemic  and  FMD-free  countries,  current  serotyp-
ing  methods  mainly  rely  either  on  antigen  detection  ELISAs  or nucleotide  sequencing  approaches.  This
report  describes  the  development  of a panel  of  serotype-speciﬁc  real-time  RT-PCR  assays  (rRT-PCR)  tai-
lored to  detect  FMDV  lineages  currently  circulating  in  East  Africa.  These  assays  target  sequences  within
the VP1-coding  region  that share  high  intra-lineage  identity,  but  do not  cross-react  with  FMD  viruses
from  other  serotypes  that  circulate  in  the  region.  These  serotype-speciﬁc  assays  operate  with  the  same
thermal  proﬁle  as  the pan-diagnostic  tests  making  it possible  to run them  in  parallel  to  produce  CT val-
ues  comparable  to the  pan-diagnostic  test  detecting  the 3D-coding  region.  These  assays  were  evaluated
alongside  the  established  pan-speciﬁc  molecular  test using  ﬁeld  samples  and  virus isolates  collected
from  Tanzania,  Kenya  and  Ethiopia  that  had  been  previously  characterised  by  nucleotide  sequencing.
Samples  (n  =  71)  representing  serotype  A  (topotype  AFRICA,  lineage  G-I),  serotype  O (topotypes  EA-2  and
EA-4),  serotype  SAT  1 (topotype  I (NWZ))  and  serotype  SAT2  (topotype  IV)  were  correctly  identiﬁed  with
these  rRT-PCR  assays.  Furthermore,  FMDV  RNA  from  samples  that did  not  contain  infectious  virus  could
still  be  serotyped  using  these  assays.  These  serotype-speciﬁc  real-time  RT-PCR  assays  can  detect  and
characterise  FMDVs  currently  circulating  in  East  Africa  and  hence  improve  disease  control  in  this  region.
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Foot-and-mouth disease (FMD) is a highly contagious viral dis-
ase affecting both wild and domesticated cloven-hooved animals.
lthough FMD  generally has a low mortality rate, it affects a large
umber of animals of multiple species leading to loss or reduction
n livestock production in endemic regions in Asia and Africa. It is
stimated that collectively three-quarters of the world’s livestock
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/).population is concentrated in FMD  endemic areas (Knight-Jones
and Rushton, 2013) leading to an enormous source of inefﬁciency
and waste in food production especially in the context of a growing
demand for livestock products. In addition, outbreaks of the disease
can spread into countries normally free of FMD  posing signiﬁcant
costs to livestock industries.
FMD  is caused by FMD  virus (FMDV), belonging to genus
Aphthovirus within the family Picornaviridae (Knowles et al.,
2012). The non-enveloped virus particle encloses a single-stranded
positive-sense RNA genome of approximately 8.3 kilobases. Seven
immunologically distinct serotypes of the virus exist: O, A, C, SAT
(Southern African Territories) 1, SAT 2, SAT 3 and Asia 1; each
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
List of primers and probes for FMDV type-speciﬁc assays in East Africa.
OLIGO NAME NUCLEOTIDE SEQUENCE (5′ → 3′)
FMDV/A/FP GCCACRACCATCCACGA
FMDV/A/RP GAAGGGCCCAGGGTTGGACTC
FMDV/A/P FAM-CTCGTGCGMATGAARCGGGC-BHQ1
FMDV/O/FP CCTCCTTCAAYTACGGTG
FMDV/O/RP GCCACAATCTTYTGTTTGTG
FMDV/O/P FAM-CCCTCTTCATGCGGTARAGCAG-BHQ1
FMDV/SAT1/FP CTYGACCGGTTCACYCTG
FMDV/SAT1/RP CCGAGAAGTAGTACGTRGC
FMDV/SAT1/P FAM-CAGGAYTGCGCCCACCA-BHQ1
FMDV/SAT2/FP CRATCCGCGGTGAYCG
FMDV/SAT2/RP CGCTTCATYCTGTAGTARACGTC
FMDV/SAT2/P FAM-TTTGGACAYGTGACCGCCG-BHQ1K. Bachanek-Bankowska et al. / Journa
ontaining multiple variants (topotypes) often restricted to spe-
iﬁc geographical locations. Global distribution of FMDV serotypes
s uneven. Currently, serotypes O and A have the widest distribution
nd are reported in most endemic virus pools.
The surface exposed capsid protein, VP1, plays an important
ole in antigenic and phylogenetic characterisation of FMDV as it
ontains major immunogenic sites, including amino acid residues
ithin the G-H loop and the C-terminus (Baranowski et al., 2000;
ackson et al., 2002). The VP1-coding nucleotide sequence varies
etween FMDV serotypes. Further classiﬁcation of viruses into
opotypes and lineages is also possible based on phylogenetic anal-
sis of the sequence of the VP1-coding region (Knowles and Samuel,
003; Samuel and Knowles, 2001). The genetic relationship of the
P1 nucleotide sequence between different strains is commonly
pplied for tracing the origin and movement of outbreak viruses
Abdul-Hamid et al., 2011; Di Nardo et al., 2014; Knowles et al.,
014).
The established methods for FMD  control, such as vaccination
nd movement restrictions (Sumption et al., 2012), are under-
inned by rapid and accurate diagnosis of clinical cases of the
isease. Currently, pan-speciﬁc real-time reverse transcription
olymerase chain reaction (rRT-PCR) assays for FMDV detection
ave been described (Callahan et al., 2002; Moniwa et al., 2007; Reid
t al., 2002, 2009). These amplify highly conserved RNA sequences
ithin the 5′-untranslated region (UTR) or the RNA polymerase
3D-coding region), respectively. As these genome regions are
ighly conserved for all seven serotypes, FMDV can be detected
ith high diagnostic sensitivity and speciﬁcity. However, rapid
dentiﬁcation of the serotype of an outbreak virus is necessary
or vaccine selection, especially in endemic countries. This is nor-
ally achieved by antigen detection ELISA and/or VP1 sequencing
Ferris and Dawson, 1988; Knowles et al., in press). With both meth-
ds often requiring virus isolation and propagation for increased
ensitivity, the time for serotype identiﬁcation and therefore for
mplementation of effective vaccination can be prolonged.
As the VP1 coding region nucleotide sequence varies according
o the serotype of FMDV, typing can be achieved by serotype-
peciﬁc detection of the VP1 coding region, ideally, without the
eed for virus propagation. Conventional RT-PCR assays targeting
he VP1 coding region have been described (Alexandersen et al.,
000; Callens and de Clercq, 1997; Vangrysperre and de Clercq,
996) but due to the high genetic diversity within the target region
hese have relatively poor sensitivity and speciﬁcity (Reid et al.,
001). A microarray-based system for typing FMDV has also been
escribed (Baxi et al., 2006) but this can be lengthy and costly and
lso requires use of specialised equipment. Sequence data analy-
is of the VP1 coding region indicates that, due to the extensive
ntra-serotype variation of the VP1 coding nucleotide sequences,
evelopment of reliable serotype speciﬁc RT-PCR assays might be
ifﬁcult to achieve on a global basis (Reid et al., 1999).
As FMDV circulation often occurs in regional reservoirs (Paton
t al., 2009), topotypes and lineages of FMDV speciﬁc to differ-
nt geographical areas have evolved. These can be identiﬁed and
haracterised based on phylogenetic analysis of the VP1 coding
equences. Exploiting the fact that genetic variability between
trains within lineages is reduced in comparison to the nucleotide
ariability within serotypes, RT-PCR assays tailored to FMDV lin-
ages and therefore geographic areas can be developed. This idea
as been applied in conventional RT-PCR systems to distinguish
etween strains of FMDV belonging to different serotypes circu-
ating in India (Giridharan et al., 2005). This system was further
eveloped and applied to serotype viruses circulating in the Mid-
le East (Reid et al., 2014), West Eurasia (Jamal and Belsham, 2015)
s well as for the detection of the SAT 2 serotype (topotype VII)
n Egypt (Ahmed et al., 2012) and the serotype O viruses in North
frica belonging to Ind-2001d lineage (Knowles et al., 2014).The names of the primers and probes indicate the type-speciﬁcity of the assays. FP,
RP or P stand for “forward primer”, “reverse primer” or “probe” respectively; R = A
or  G, Y = C or T and M = A or C.
This study describes the development of a set of typing rRT-PCR
assays tailored to detect FMDV viruses currently circulating in East
Africa, with a particular focus on Tanzania, Kenya and Uganda.
2. Materials and methods
2.1. Primers and probe design
The design of primers and probes was  based on nucleotide
sequences encoding VP1 originating from East Africa obtained from
GenBank (http://www.ncbi.nlm.nih.gov/).
The VP1 coding region sequences were aligned using BioEdit
(Hall, 1999) and analysed collectively and separately for serotypes
A, O, SAT 1 and SAT 2. Following the analyses, unique regions of the
VP1 coding sequence were identiﬁed as targets for primers and
probes for each serotype, in accordance with TaqMan speciﬁca-
tions. However, to achieve satisfactory results in the type A assay,
a modiﬁed NK72 primer of broad speciﬁcity that anneals to the
nucleotide sequence at the junction of 2A and 2B coding region
(Knowles et al., in press), was  used as the reverse primer. Each
oligonucleotide (oligo) set was evaluated in silico to ensure diagnos-
tic speciﬁcity between the different lineages within the serotypes
without a compromise on cross-reactivity between serotypes.
All oligonucleotides were synthesised by Sigma-Aldrich (USA)
and all probes were labelled with BHQ-1 (Black Hole Quencher-1)
and FAM at their 3′ and 5′ termini, respectively.
At least two  candidate oligo sets (primers and probe) were
designed for each of the assays and evaluated in multiple possible
combinations for detection of the homologous serotype. The best
performing oligo was selected for each of the respective assays.
Table 1 lists the sequences of the best performing oligo sets.
2.2. Virus isolates
A panel of FMDV clinical samples (n = 61) and virus isolates
(n = 10) was selected from the sample repository held at the World
Reference Laboratory for FMD  (WRLFMD) (The Pirbright Institute,
UK) and contemporary diagnostic submissions from East Africa
(Fig. 1). These included FMDV samples previously characterised as
serotype A, topotype AFRICA, lineage G-I; serotype O, topotype EA-
2 and EA-4; serotype SAT 1, topotype I (NWZ) and serotype SAT 2,
topotype IV. Virus was  isolated from these samples and tested with
antigen ELISA (Ag-ELISA) to establish the FMDV serotype (Ferris
and Dawson, 1988). Samples that originated from East Africa, from
which FMDV RNA was  detected by rRT-PCR (Callahan et al., 2002),
but neither virus isolation nor Ag-ELISA were positive (TAN/9/2013,
TAN/16/2013,TAN/18/2013, TAN/23/2013 and TAN/28/2013) were
also included in the panel.
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Serotype O
Serotype A
Serotype SAT1
Serotype SAT2
Sample name origin 3D assay type O type A type SAT1 type SAT2
KEN/15 /201 1 cli nical 31 .34 30 .95 No C t No C t No C t
KEN/16 /201 1 cli nical 25 .02 27 .61 No C t No C t No C t
KEN/137 /2010 * cli nical 23 .83 37 .90 23 .18 No C t No C t
KEN/151/2010 clinical 14.46 23.51 No Ct No Ct No Ct
TAN/39 /201 2 cli nical 13 .50 16 .51 No C t No C t No C t
KEN/145 /201 0 cli nical 15 .56 17 .94 No C t No C t No C t
KEN/146 /201 0 cli nical 12 .37 13 .86 No C t No C t No C t
TAN/16 /200 8 cli nical 18 .47 21 .08 No C t No C t No C t
KEN/10/2009 clinical 20.41 34.97 No Ct No Ct No Ct
KEN/154 /201 0 cli nical 19 .90 21 .14 No C t No C t No C t
TAN/5/200 9 cli nical 16 .23 15 .75 No C t No C t No C t
KEN/11/2011 clinical 25.18 27.45 No Ct No Ct No Ct
KEN/1/2011 clinical 15.39 16.34 No Ct No Ct No Ct
KEN/148/2010 clinical 15.46 16.88 No Ct No Ct No Ct
KEN/152/2010 clinical 13.70 14.45 37.99 No Ct No Ct
KEN/100/2010 T/C 21.60 22.35 No Ct No Ct No Ct
ETH/04 /201 3 T/C 15 .64 20 .83 No C t No C t No C t
ETH/8/2013 T/C 27.45 28.65 No Ct No Ct No Ct
ETH/13 /201 3 T/C 25 .45 24 .15 No C t No C t No C t
ETH/14 /201 3 T/C 25 .25 23 .95 42 .40 No C t No C t
TAN/7/201 3 cli nical 14 .56 No C t 17 .51 No C t No C t
TAN/5/201 3 cli nical 10 .48 No C t 13 .88 No C t No C t
TAN/6/2013 clinical 11.60 No Ct 11.87 No Ct No Ct
TAN/14 /201 3 cli nical 14 .90 No C t 17 .43 No C t No C t
TAN/15 /201 3 cli nical 11 .07 No C t 13 .43 No C t No C t
TAN/1/201 3 T/C 13 .24 No C t 14 .78 No C t No C t
TAN/61 /201 2 T/C 18 .25 No C t 18 .87 No C t No C t
TAN/71 /201 2 T/C 15 .74 No C t 15 .99 No C t No C t
TAN/42/2009 clinical 18.45 No Ct 18.86 No Ct No Ct
TAN/45/2009 clinical 16.03 No Ct 15.97 No Ct No Ct
KEN/28 /200 8 cli nical 18 .37 No C t 18 .67 No C t No C t
TAN/26 /201 3 cli nical 13 .99 No C t 18 .10 No C t No C t
KEN/22 /200 9 cli nical 23 .23 No C t 21 .80 No C t No C t
KEN/5/201 2 T/C 16 .05 No C t 16 .94 No C t No C t
KEN/6/201 2 T/C 14 .15 No C t 14 .42 No C t No C t
TAN/20 /201 3 cli nical 12 .98 No C t 34 .70 16 .85 No C t
TAN/21 /201 3 cli nical 13 .43 No C t 38 .23 17 .85 No C t
TAN/22 /201 3 cli nical 15 .43 No C t No C t 18 .99 No C t
TAN/25 /201 3 cli nical 12 .50 No C t No C t 16 .23 No C t
TAN/27 /201 3 cli nical 7.49 No C t No C t 20 .05 No C t
TAN/24 /201 3 cli nical 11 .88 No C t No C t 15 .88 No C t
TAN/49 /201 2 cli nical 12 .44 No C t No C t 13 .77 36 .33
TAN/50 /201 2 cli nical 12 .63 No C t No C t 13 .53 No C t
KEN/16 /200 9 cli nical 15 .12 28 .67 No C t 16 .16 No C t
KEN/26 /200 8 cli nical 13 .84 No C t No C t 15 .39 No C t
KEN/9/200 9 cli nical 15 .95 No C t No C t 17 .47 No C t
KEN/139 /201 0 cli nical 21 .07 No C t No C t 17 .73 No C t
KEN/71 /201 0 cli nical 18 .71 No C t No C t 21 .17 No C t
KEN/72 /201 0 cli nical 14 .17 No C t No C t 16 .16 No C t
KEN/140 /201 0 cli nical 19 .97 No C t No C t 21 .66 No C t
KEN/1/201 0 cli nical 22 .83 No C t No C t 23 .76 No C t
KEN/121 /200 9 cli nical 21 .76 36 .88 No C t 23 .39 No C t
KEN/12 /200 9 cli nical 16 .44 No C t No C t 18 .31 No C t
KEN/123 /200 9 cli nical 31 .65 No C t No C t 19 .83 No C t
TAN/7/201 1 cli nical 19 .85 No C t No C t No C t 22 .07
KEN/12 /201 1 cli nical 15 .32 No C t No C t No C t 17 .89
TAN/6/201 1 cli nical 20 .14 No C t No C t No C t 21 .90
TAN/3/201 1 cli nical 18 .92 No C t No C t No C t 19 .11
KEN/21 /201 1 cli nical 13 .27 35 .59 No C t No C t 15 .68
TAN/64 /201 2 cli nical 17 .56 No C t No C t No C t 20 .07
TAN/14 /201 2 cli nical 14 .06 No C t No C t No C t 15 .17
TAN/16 /201 2 cli nical 17 .96 No C t No C t No C t 18 .32
TAN/19 /201 2 cli nical 15 .95 No C t No C t No C t 15 .81
KEN/2/200 7 cli nical 21 .04 No C t No C t No C t 25 .40
KEN/11 /200 7 cli nical 17 .70 No C t No C t No C t 19 .91
KEN/2/200 8 cli nical 15 .07 No C t No C t No C t 16 .23
Fig. 1. Details of the FMDV positive samples by virus isolation used in this study. Phylogenetic comparisons are based on the analysis of VP1 coding sequence. T/C stands for
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Sample KEN/137/2010 sequence data was obtained from virus propagated in tissu
rom  clinical samples.
Additionally 27 ﬁeld samples collected in Tanzania were tested
n the Tanzania Veterinary Laboratory Agency (TVLA) to conﬁrm
he diagnostic performance of the developed assays in an African
etting.
.3. RNA sample preparationNucleic acid was extracted either using an automated extrac-
ion platform, MagNA Pure (Roche) as previously described (Reid
t al., 2003) or manually using a QIAamp Viral RNA MiniKit (Qiagen)
ccording to the manufacturer’s instructions. Each of the isolatesure (BTy2) (serotype O) while rRT-PCR results (serotype A) were obtained directly
was handled with care to avoid any cross-contamination. The viral
RNA was stored at −70 ◦C until used in the experiments.
2.4. RT-PCR
The respective primers and probe sets were designed to per-
form under the same protocol and ampliﬁcation conditions as those
described earlier for the pan-FMDV assays (Shaw et al., 2007) with
the view that pan-speciﬁc and tailored assays could be performed in
parallel on the same reaction plate. FMDV samples were also tested
using a pan-speciﬁc assay detecting the 3D-coding region (Callahan
et al., 2002) to validate the results. All reactions were performed in
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uplicate, set up manually and ampliﬁed in a Stratagene Mx3005P
hermal cycler.
The ampliﬁcation efﬁciency of each of the respective typing
ssays was estimated on the basis of a 10-fold dilution of a represen-
ative sample for each serotype (serotype O: ETH/4/2013; serotype
: TAN/45/2009; serotype SAT 1: KEN/136/2010; serotype SAT 2:
EN/21/2011). The efﬁciency was calculated by the following for-
ula: E% = 10−1/slope × 100.
.5. Sequencing
The VP1 sequences were generated using the standard method
nd primers (Knowles et al., in press) by 3730 DNA Analyzer (ABI),
ccording to the manufacturer’s instructions and assembled using
eqMan Pro 13 Software (DNAStar Inc., USA). Sequence data were
ligned using CLUSTAL W v1.83 software (Thompson et al., 1994)
nd phylogenetic trees constructed by Neighbor-Joining method.
he evolutionary distances were computed using the Kimura 2-
arameter method in MEGA version 6.06 software (1000 bootstrap
eplicates) (Tamura et al., 2013).
. Results
.1. Diagnostic sensitivity and speciﬁcity of type-speciﬁc rRT-PCR
ssays
A panel of 68 RNA samples representing FMD  viruses of
erotypes O, A, SAT 1 and SAT 2 circulating in Kenya, Tanzania
nd Ethiopia collected between 2007 and 2013 was tested using
he type-speciﬁc rRT-PCR assays. Results for duplicate RNA sam-
les were directly compared to those of the 3D rRT-PCR assay
Callahan et al., 2002). All FMDV RNA samples were detected by
he assay targeting the 3D-coding region and the serotype of these
ositive samples was determined using the corresponding type-
peciﬁc rRT-PCR assay, identifying virus type with comparable CT
alues in most cases (Fig. 1). Mean CT values for the 3D assay and
erotype-speciﬁc assays (O, A, SAT 1 and SAT 2) were calculated for
he isolates tested showing that, on average, isolates were detected
arlier with the pan-speciﬁc 3D assay with a reduction of 2.9, 1.1,
.7 and 1·7 CT values, respectively. The virus type identiﬁed by
he type-speciﬁc real-time RT-PCR assay was conﬁrmed from VP1
ucleotide sequence data (data not shown).
In nine RNA samples, a positive signal was produced with two
ifferent serotype-speciﬁc assays. In seven of these, the serotype
f the virus was correctly identiﬁed by the assay which pro-
uced a CT value similar to the CT value of the 3D targeted assay,
hile the second assay produced a CT value >12.44 higher in the
anel of samples tested. However, in sample KEN/137/2010, which
as characterised by VP1 sequencing and Ag-ELISA (WRLFMD
eport: http://www.wrlfmd.org/fmd genotyping/2011/WRLFMD-
011-00008%20O%20Kenya%202010-2011.pdf) as serotype O, RNA
f FMDV serotypes A and O was detected. In the type A-speciﬁc
RT-PCR assays the CT value (23.18) was comparable to the 3D pan-
peciﬁc assay (23.83), while the serotype O signal was weaker (CT
alue of 37.90). The A type-speciﬁc rRT-PCR assay amplicon was
equenced, conﬁrming the presence of the serotype A RNA in this
ample. The amplicon sequence was compared to other known
ontemporary serotype A sequences from the geographical area
howing that this virus in KEN/137/2010 has a novel sequence not
reviously handled at the Pirbright Laboratory (data not shown).
In addition to samples that had been previously characterised
y Ag-ELISA and/or VP1 sequencing, the virus serotype was  iden-
iﬁed in ﬁve samples in which the FMDV genome was detected
ith the pan-speciﬁc assay targeting the 3D region but which
ere negative by virus isolation methods. FMDV type A-speciﬁcological Methods 237 (2016) 114–120 117
assay produced a positive signal in three of the samples tested
(TAN/9/2013, TAN/16/2013 and TAN/18/2013) while SAT 1 virus
template was detected with the SAT 1-speciﬁc assay in two other
samples (TAN/23/2013 and TAN/28/2013). The CT values in each
case were comparable to the CT value of the 3D targeting assay.
3.2. Analytical sensitivity
The comparative analytical sensitivity of the type-speciﬁc
assays was  evaluated based on ten-fold dilution series of homol-
ogous viral RNA performed in duplicated in direct comparison to
the pan-speciﬁc assay. Dilutions of homologous viral RNA were
detected at similar CT values for each of the type-speciﬁc assays
in comparison to the pan-speciﬁc assay. However, the A and SAT 2-
speciﬁc assays detected seven serial dilution of the RNA template,
while type O- and SAT 1-speciﬁc assays yielded positive results with
six dilutions, one fewer than the pan-speciﬁc assay (Fig. 2).
The efﬁciency of the respective type-speciﬁc assays varied
between 92.9 and 101.3% and was  comparable to that of the
assay detecting the 3D coding region (efﬁciency between 89.2 and
100.2%) (Fig. 2), conﬁrming similar robustness of the type-speciﬁc
assay to that of the 3D speciﬁc assay.
3.3. Evaluation of assays in East Africa
The performance of the type-speciﬁc assays was  further eval-
uated alongside the pan-speciﬁc 3D assay (Callahan et al., 2002)
in the Tanzania Veterinary Laboratory Agency where an additional
panel of 27 clinical samples collected in Tanzania between 2008
and 2013, two FMDV positive controls and a negative control were
tested. All samples, apart from the negative control, were detected
with the pan-speciﬁc assay targeting the 3D region with CT values
ranging from 10.19 to 37.17. The type-speciﬁc CT values ranged
from 9.72 to 31.89 with all but the negative control and two  sam-
ples (#29 and #179) which produced a weak 3D signal (CT 37.17 and
34.32, respectively) (Table 2). The type-speciﬁc signal gave a clear
indication of the serotype for the majority of samples, however, a
positive signal was recorded in sample #374 with two type-speciﬁc
assays – A and SAT 1, possibly indicating a mix  infection. A high
CT value (31.90–39.02) was recorded with a number of samples
indicating detection of a low level of viral RNA.
4. Discussion
The availability of rapid, reliable and accurate diagnostic meth-
ods is important for effective control and surveillance strategies for
FMD. Methods for the detection of FMDV such as virus isolation,
conventional and rRT-PCR are widely used while the repertoire of
serotyping methods (e.g. ELISA) is more limited (OIE, 2012). The
serotyping antigen ELISA often relies on initial virus isolation and
propagation and requires access to standard biological reagents
(Ferris and Dawson, 1988). These factors may  extend the period for
implementation of control strategies especially in endemic coun-
tries and make surveillance strategies labour- and cost-intensive.
The FMDV genome region encoding the capsid proteins, par-
ticularly the VP1 coding sequence, varies according to serotype.
However, the high level of intra-serotype nucleotide variability
makes it difﬁcult to design broadly reacting molecular tests that
can detect all representatives of a single FMDV serotype that are
circulating in different geographical regions (Reid et al., 2014).
Instead, a number of molecular assays tailored to a speciﬁc lineage
found in more restricted geographical locations have been success-
fully developed (Ahmed et al., 2012; Jamal and Belsham, 2015;
Knowles et al., 2014; Reid et al., 2014). This study also employed
this approach and describes the design and validation of FMDV
type-speciﬁc assays tailored for the FMD  viruses from East Africa.
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Fig. 2. Comparison of detection of serial diluted viral RNA 
FMDV circulation often occurs within regional reservoirs where
trains speciﬁc to the region evolve (Paton et al., 2009). Thus, mainly
our serotypes of FMDV (O, A, SAT 1 and SAT 2) have been described
o circulate in East Africa. Within each serotype, a restricted num-
er of topotypes/lineages have been identiﬁed, namely: topotype
A-2 and EA-4 in FMDV O, topotype AFRICA, lineage G-I in FMDV
, topotype I (NWZ) in FMDV SAT1 and topotype IV in FMDV SAT2
Kasambula et al., 2012; Kasanga et al., 2015; Namatovu et al., 2015;
ekesa et al., 2014, 2015a,b). In this study, a set of four serotype-
peciﬁc TaqMan technology based assays was designed, tailored
o detect the various FMDV serotypes currently circulating in East
frica. This was achieved by targeting the serotype-speciﬁc VP1
oding sequence in most cases. However, the reverse primer in
he FMDV-A speciﬁc assay was designed to anneal to the more
onserved 2A/2B coding region of the genome, due to high het-
rogeneity within the VP1 coding region of the analysed strains.
As intended, the assays were shown to speciﬁcally identify
he homologous viruses in all assays with the CT values similar
o those of the pan-speciﬁc test detecting the 3D coding region,
dentifying the serotype of the sample. In addition to studies under-
aken in Europe (at The Pirbright Institute), validation experiments
ere also conducted at the Tanzania Veterinary Laboratory Agency
howing that rapid and reliable identiﬁcation of the virus type can
e achieved in an endemic setting. In some samples, however, a
ositive signal was recorded in more than one of the serotype-
peciﬁc RT-PCR assays. This could be indicative of a mixed infection,
 laboratory contamination or poor speciﬁcity of the developed
ests. However, in silico analyses of the respective oligo-templateNumber of se ria l diluons  
-speciﬁc (3D-speciﬁc) and individual type-speciﬁc assays.
annealing regions indicated high speciﬁcity of these assays. In addi-
tion, the assay’s speciﬁcity was investigated by sequencing of the
amplicons and the presence of VP1 templates as identiﬁed by the
developed rRT-PCR assays was conﬁrmed in each case.
The analysis of the results obtained from testing different pas-
sages of the KEN/137/2010 sample give insight into the veracity
of the assays developed. FMDV from this clinical sample was
isolated and passaged twice in BTy cells and the serotype was
identiﬁed as FMDV-O in Ag-ELISA by the WRLFMD laboratory (The
Pirbright Institute). The VP1 sequence of the same serotype was
also obtained on the virus isolate conﬁrming the results of sero-
logical typing. However, when RNA extracted directly from the
clinical material was tested with the developed typing rRT-PCR
assays, the presence of two serotypes was identiﬁed. The FMDV-
O speciﬁc assay produced a late signal (high CT value) (indicating
a low level of the serotype O genetic material) and the FMDV-A
speciﬁc assay generated a lower CT value comparable to the pan-
speciﬁc assay, indicating that the predominant serotype in the
initial sample was  FMDV-A. The rRT-PCR amplicon of the FMDV-
A speciﬁc assay was subsequently sequenced and compared to
FMDV-A sequences available in the WRLFMD database showing
it as a novel sequence. These results lead to a conclusion that the
FMDV-O component of the virus present in the clinical samples may
have become dominant during subsequent cell passages outcom-
peting the predominant A virus which was present in the clinical
sample. Alternatively, laboratory contamination could have played
a role.
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Table  2
Validation of the serotype speciﬁc assays in laboratory settings in Tanzania.
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These data also show that the rRT-PCR assays can be used on
pecimens where virus isolation is not available or not possible. This
eature gives the ability to obtain epidemiological information even
rom samples not suitable for serotyping by Ag-ELISA. The ability
o establish the type of the virus by selective genome ampliﬁcation
akes this set of type-speciﬁc assays suitable for further applica-
ions such as adaptation for mobile diagnostic platforms (Howson
t al., 2015; Madi et al., 2012) and/or validation for use in combina-
ion with nucleic acid recovered from lateral-ﬂow devices (Fowler
t al., 2014). Furthermore, the type-speciﬁc assays operate with the
ame thermal proﬁle as the pan-diagnostic tests making it possible
o multiplex diagnostic and serotyping tests further enhancing the
otential for these assays.
These ﬁndings highlight the validity of the East African serotyp-
ng RT-PCR assay in a wide range of applications including testing
or mixed infection or lab contamination of viral RNA samples
esigned for further downstream applications such as production
f diagnostic sera. FMDV is a rapidly evolving virus and the devel-
ped assays target the most variable region of its genome. It is
herefore possible that, with time, new lineages will evolve or
trains are discovered with signiﬁcant changes within the oligo
nnealing sites, prohibiting normal function of these assays. It is
herefore recommended that such assays are not used alone as afront line diagnostic test but are used in combination with pan-
speciﬁc diagnostic approaches.
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